MiniMed Group, Inc.
MMED Healthcare Medical Instruments & Supplies
MiniMed Group, Inc.’s revenue for fiscal 2026 (year ended April 2026) was $3.1 billion, up 14.3% from fiscal 2025.
Follow MMED
Alert me
MiniMed Group, Inc. (MMED) Free cash flow
MiniMed Group, Inc.'s free cash flow for fiscal 2026 was −$420.0M, compared with −$53.0M in fiscal 2025. Over the twelve months to 31 July 2026 it was −$452.0M. MiniMed Group, Inc. ranks 51st of 51 Medical Instruments & Supplies companies by free cash flow.
Free cash flow, annual
Embed this chart
Annual newest first
| Period | Free cash flow | Change |
|---|---|---|
| FY2026 | −$420.0M | — |
| FY2025 | −$53.0M | — |
| FY2024 | −$107.0M | — |
Quarterly newest first
| Period | Free cash flow | Change |
|---|---|---|
| Jul 2026 | −$90.0M | — |
| Jan 2026 | −$194.0M | — |
| Jul 2025 | −$194.0M | — |
| Apr 2025 | $26.0M | — |
| 2 more quarters | Free account |
Free cash flow against peers
| Company | Free cash flow |
|---|---|
| ICUI ICU Medical, Inc. compare | $272.2M |
| BLCO Bausch + Lomb Corporation compare | $252.0M |
| NVST Envista Holdings Corporation compare | $244.6M |
| MMSI Merit Medical Systems, Inc. compare | $225.8M |
| TFX Teleflex Incorporated compare | $53.1M |
| ATRC AtriCure, Inc. compare | $52.9M |
| STVN Stevanato Group S.p.A. compare | −$8.8M |
| PLSE Pulse Biosciences, Inc compare | −$216.1M |
| MMED MiniMed Group, Inc. | −$452.0M |
What Free cash flow is
Free Cash Flow tells an investor how much cash a company’s operations generate after paying for its investment in physical and intangible assets.
Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)
More on MMED
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Shares outstanding
- Book value per share
- The full statement